Eli Lilly prepares for FDA rejection of eczema treatment

Following two delays to the FDA’s final decision, Eli Lilly now says that the approval of a new indication in the US might not be in the cards for its eczema drug for adults, Olumiant.
Photo: Darron Cummings/AP/Ritzau Scanpix
Photo: Darron Cummings/AP/Ritzau Scanpix
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen

Eli Lilly’s tug-of-war with the US Food and Drug Administration (FDA) over the treatment for adults with atopic eczema, Olumiant (baricitinib), is currently not looking to end favorably for the US-based pharmaceutical company.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading